Physician profile
Philip J Ryan
NPI 1043396229
$35,389.75
in general payments reported to CMS, 2019-2025
43 companies · $1,958 in 2025
The $1,958 reported for 2025 was more than what 76% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17K · 2020: $7,675 · 2021: $3,581 · 2022: $1,728 · 2023: $1,618 · 2024: $1,954 · 2025: $1,958.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,530.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,529.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $11,399.35 | 2019-2022 | |
| Abbvie INC. | $9,438.74 | 2019-2025 | Synthroid |
| Esperion Therapeutics, INC. | $4,317.99 | 2020-2025 | Nexletol |
| Lilly USA, LLC | $2,658.31 | 2019-2025 | Mounjaro, Jardiance, Lyumjev |
| Novo Nordisk INC | $1,247.53 | 2019-2025 | Ozempic, Rybelsus, Tresiba |
| Boehringer Ingelheim Pharmaceuticals, INC. | $826.64 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Abbott Laboratories | $647.24 | 2021-2025 | Freestyle Libre 3 |
| Amgen INC. | $642.16 | 2019-2025 | Tepezza, Evenity, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $636.25 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $525.96 | 2019-2025 | |
| Corcept Therapeutics | $491.68 | 2019-2025 | Korlym |
| Antares Pharma, INC. | $319.36 | 2022-2025 | Xyosted, Tlando, Nocdurna |
| Dexcom, INC. | $312.37 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $261.76 | 2019-2020 | |
| Xeris Pharmaceuticals, INC. | $210.16 | 2021-2025 | Gvoke Hypopen, Recorlev |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Ryan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.